442 material Form 8-K filings that 386 companies we cover made with the SEC in March 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Cintas reported fiscal 2025 third-quarter revenue of $2.61 billion, up 8.4%, and diluted EPS of $1.13, up 17.7% from $0.96 a year earlier. The company raised its fiscal 2025 diluted EPS guidance to $4.36 to $4.40 from $4.28 to $4.34, while narrowing its revenue guidance to $10.280 billion to $10.305 billion.
Q3 net income was $463.5 million, up 16.6%, and gross margin was 50.6% of revenue versus 49.4% a year earlier.
Q3 operating income included a $15.0 million gain on the sale of property and equipment; the prior-year quarter included a $15.0 million class action settlement charge.
Fiscal 2025 diluted EPS guidance rose to $4.36 to $4.40 from $4.28 to $4.34.
Fiscal 2025 revenue guidance is $10.280 billion to $10.305 billion, versus the prior $10.255 billion to $10.320 billion; the top end was lowered by $15.0 million due to currency effects.
Jabil reported preliminary, unaudited second-quarter fiscal 2025 results with net revenue of $6.7 billion, roughly flat with $6.8 billion a year earlier, and core diluted EPS of $1.94, up from $1.68. GAAP diluted EPS fell to $1.06 from $7.31 because the prior-year quarter included a $944 million divestiture gain. The company also raised its fiscal 2025 outlook, with core diluted EPS now expected at $8.95 and third-quarter net revenue guided to $6.7 billion to $7.3 billion.
Q2 net revenue $6.7 billion ($6,728 million) versus $6,767 million a year earlier
Q2 core diluted EPS $1.94 versus $1.68; GAAP diluted EPS $1.06 versus $7.31, which included a prior-year divestiture gain
Fiscal 2025 outlook: net revenue $27.9 billion, core operating margin 5.4%, core diluted EPS $8.95, adjusted free cash flow $1.2 billion or more
Q3 fiscal 2025 guidance: net revenue $6.7 billion to $7.3 billion; core diluted EPS $2.08 to $2.48
ABM reported first-quarter fiscal 2025 revenue of $2.1 billion, up 2.2%, with net income of $43.6 million, or $0.69 per diluted share, versus $0.70 a year earlier. The company raised the low end of its full-year adjusted EPS outlook by $0.05 to a range of $3.65 to $3.80 and declared a $0.265 quarterly dividend, but free cash flow was negative $122.9 million, which management attributed mainly to a temporary working capital increase during its new ERP system transition.
Revenue of $2.1 billion, up 2.2%, including 1.6% organic growth; Technical Solutions revenue rose 21.9% and Aviation rose 8.2%
Net income of $43.6 million ($0.69 per diluted share) vs. $44.7 million ($0.70) a year earlier; adjusted EPS of $0.87 vs. $0.86
Fiscal 2025 adjusted EPS outlook now $3.65 to $3.80; adjusted EBITDA margin forecast unchanged at 6.3% to 6.5%
Free cash flow was negative $122.9 million vs. negative $13.7 million; quarterly dividend of $0.265 payable May 5, 2025 to holders of record April 3, 2025
For the fiscal second quarter ended February 1, 2025, UNFI reported net sales up 4.9% to $8.2 billion and a net loss of $3 million, or $0.05 per diluted share, versus a $15 million loss a year earlier. The company raised its fiscal 2025 outlook for most metrics, including Adjusted EPS of $0.70 to $0.90, up from $0.40 to $0.80. Both sales and per-share results improved, though the company still posted a GAAP loss for the quarter.
Net sales rose 4.9% to $8.2 billion, driven by a 3% increase in wholesale unit volumes and inflation.
Net loss narrowed to $3 million ($0.05 per diluted share) from $15 million ($0.25); Adjusted EPS was $0.22 versus $0.07.
Adjusted EBITDA rose 13.3% to $145 million; net debt to Adjusted EBITDA ratio fell to 3.7x from 4.3x a year earlier.
Fiscal 2025 outlook raised from the December 10, 2024 guidance: net sales now $31.3 billion to $31.7 billion and free cash flow above $150 million.
DICK'S Sporting Goods reported fourth quarter and full year 2024 results, with fourth quarter net sales of $3.89 billion, up 0.5%, and full year diluted EPS of $14.05, up from $12.18. The company guided 2025 diluted EPS to $13.80 to $14.40 and raised its quarterly dividend 10% to $1.2125 per share, and its board approved a new $3 billion share repurchase program.
Q4 comparable sales rose 6.4%; the fourth quarter had 13 weeks versus 14 in the prior-year period, and the calendar shift reduced net sales by about $30 million.
Q4 GAAP diluted EPS was $3.62, up from $3.57; non-GAAP diluted EPS was $3.62 versus $3.85 a year earlier.
2025 outlook: comparable sales growth of 1.0% to 3.0%, net sales of $13.6 billion to $13.9 billion, and diluted EPS of $13.80 to $14.40.
Dividend of $1.2125 per share payable April 11, 2025, to holders of record on March 28, 2025; new $3 billion repurchase program is in addition to the remaining amount of the $2 billion program authorized December 16, 2021.
Abercrombie & Fitch reported fourth quarter and fiscal 2024 results on March 5, 2025, with full-year net sales up 16% to $4.95 billion and diluted earnings per share of $10.69, compared with $6.22 a year earlier. The Board also authorized a new $1.3 billion share repurchase program with no expiration date, and the company gave fiscal 2025 guidance of 3% to 5% net sales growth and net income per diluted share of $10.40 to $11.40.
Fourth quarter net sales were $1.58 billion, up 9%, with comparable sales up 14%.
Full-year operating margin was 15.0%, up from 11.3% in fiscal 2023.
Full-year diluted EPS was $10.69 versus $6.22; the 2025 outlook is $10.40 to $11.40.
The new $1.3 billion authorization replaces the 2021 program; the company expects $400 million in share repurchases in 2025.
CooperCompanies reported fiscal first-quarter 2025 results for the period ended January 31, 2025, with revenue up 4% to $964.7 million and GAAP diluted EPS of $0.52, compared with $0.41 a year earlier. The company also raised the low end of its fiscal 2025 non-GAAP diluted EPS guidance to $3.94 to $4.02, from $3.92 to $4.02, which gives shareholders a higher expected earnings floor for the year.
Q1 revenue of $964.7 million, up 4% from $931.6 million a year earlier; up 5% in constant currency and organically
GAAP diluted EPS of $0.52 vs. $0.41; non-GAAP diluted EPS of $0.92 vs. $0.85
Fiscal 2025 non-GAAP diluted EPS guidance raised to $3.94 to $4.02 from $3.92 to $4.02
Fiscal 2025 total revenue guidance of $4,080 million to $4,158 million, with organic growth of 6% to 8%
Burlington Stores reported fourth-quarter fiscal 2024 comparable store sales growth of 6%, above its 0% to 2% guidance, and adjusted EPS of $4.13, up 12% and above its $3.55 to $3.75 guidance range. For full fiscal 2024, adjusted EPS was $8.35, up 34%, but the company said the 2025 outlook is very uncertain and guided first-quarter adjusted EPS of $1.30 to $1.45, below the $1.42 reported a year earlier.
Q4 net income was $261 million, or $4.02 per diluted share, versus $227 million, or $3.53 per share, in the prior year's 14-week period.
Q4 adjusted EPS was $4.13 versus guidance of $3.55 to $3.75.
Fiscal 2025 adjusted EPS is guided to $8.70 to $9.30, compared with $8.35 in fiscal 2024.
First-quarter fiscal 2025 adjusted EPS is guided to $1.30 to $1.45, compared with $1.42 a year earlier.
Kodiak Gas Services reported fourth-quarter 2024 net income attributable to common shareholders of $19.1 million, compared with a net loss of $6.9 million a year earlier, and full-year net income of $49.9 million versus $20.1 million in 2023. The company also issued 2025 guidance, including adjusted EBITDA of $685 million to $725 million, which gives shareholders a first benchmark for the coming year.
Q4 2024 total revenues were $309.5 million, up from $226.0 million in Q4 2023 but down from $324.6 million in Q3 2024.
Full-year 2024 adjusted EBITDA was $609.6 million, compared with $438.1 million in 2023.
2025 guidance: adjusted EBITDA of $685 million to $725 million and growth capital expenditures of $240 million to $280 million.
The company repurchased 1.4 million shares in 2024 at a weighted average price of $27.88 and reported $322.5 million available on its ABL Facility.
TG Therapeutics reported fourth-quarter and full-year 2024 results, with full-year total revenue of $329.0 million and net income of $23.4 million, compared with $233.7 million and $12.7 million in 2023. The company set a 2025 target of approximately $540 million in total global revenue and said its $311.0 million in cash, cash equivalents and investment securities, combined with projected BRIUMVI revenue, should fund the business under its current operating plan.
Q4 2024 total revenue was $108.2 million, compared with $44.0 million in Q4 2023; Q4 2024 net income was $23.3 million, compared with a net loss of $14.4 million.
Full-year 2024 total revenue was $329.0 million, compared with $233.7 million in 2023; 2023 included recognition of a one-time $140.0 million Neuraxpharm upfront payment.
2025 target total global revenue is approximately $540 million, including BRIUMVI U.S. net product revenue of approximately $525 million.
Cash, cash equivalents and investment securities were $311.0 million as of December 31, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.